Fabiao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fabiao Zhang has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Ting Chen
Department of Hepatopancreatobiliary Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China
3 shared publicationsYu Zhu
Department of Hepatopancreatobiliary Surgery Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University Taizhou People's Republic of China
3 shared publications- Yu Zhu
Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Hepatobiliary Surg, 150 Ximen Rd, Taizhou 317000, Peoples R China
3 shared publications Guo-Qun Zheng
Department of Hepatopancreatobiliary Surgery, Enze Hospital of Taizhou, Taizhou, China
2 shared publicationsLing-Ling Gu
Department of Hepatopancreatobiliary Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China
2 shared publicationsPeng Hu
Department of Hepatopancreatobiliary Surgery Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University Taizhou People's Republic of China
2 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1901516
ZC3H15 in human tumors: a pan-cancer exploration of its clinical significance, molecular function, and association with the tumor immune microenvironment
Background: Zinc finger CCCH-type protein 15 (ZC3H15) is a ribosome-associated eukaryotic protein involved in many biological processes, including gene expression regulation, translation, and immune modulation. Although ZC3H15 has been implicated in the development of certain tumors, its expression, functional relevance, diagnostic potential, and prognostic value in a pan-cancer context remain not fully elucidated. This study conducts an integrative, systematic, and comparative analysis of ZC3H15 across 33 cancer types and subsequently provides further experimental validation in liver cancer. Methods: mRNA expression data of ZC3H15 were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Protein level validations were performed using the Human Protein Atlas (HPA) database and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The cBioPortal database was used to analyze the genomic alteration of ZC3H15. Two pathway enrichment analysis methods were conducted to explore the biological functions and molecular mechanisms of ZC3H15 in pan-cancer. Results: The results indicated that ZC3H15 was overexpressed in a wide range of tumors. In certain cancers, particularly LIHC, LUAD, BRCA, LUSC, and HNSC, its expression was significantly correlated with poor patient prognosis. Mutations and amplifications were the most common gene alterations in ZC3H15. The GSCA database showed that methylation levels were reduced in most tumor types. Abnormal expression of ZC3H15 was related to immune cell infiltration. Gene enrichment analysis indicated that ZC3H15-related genes involved in tumor progression were significantly enriched in multiple cell cycle processes. We demonstrated that knockdown of ZC3H15 suppressed cell proliferation, migration, and invasion in two liver cancer cell lines, MHCC97H and Huh7, and two BRCA cell lines, MDA-MB-231 and Hs 578T. To further clarify the functional mechanism, subsequent immunofluorescence staining confirmed that ZC3H15 knockdown induced prometaphase arrest in MHCC97H and Huh7 liver cancer cells. Conclusions: Overall, this pan-cancer study demonstrates that ZC3H15 serves as a potential biomarker for cancer diagnosis, prognosis, and immune cell infiltration.
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1901516
Open AccessZC3H15 in human tumors: a pan-cancer exploration of its clinical significance, molecular function, and association with the tumor immune microenvironment
Background: Zinc finger CCCH-type protein 15 (ZC3H15) is a ribosome-associated eukaryotic protein involved in many biological processes, including gene expression regulation, translation, and immune modulation. Although ZC3H15 has been implicated in the development of certain tumors, its expression, functional relevance, diagnostic potential, and prognostic value in a pan-cancer context remain not fully elucidated. This study conducts an integrative, systematic, and comparative analysis of ZC3H15 across 33 cancer types and subsequently provides further experimental validation in liver cancer. Methods: mRNA expression data of ZC3H15 were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Protein level validations were performed using the Human Protein Atlas (HPA) database and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The cBioPortal database was used to analyze the genomic alteration of ZC3H15. Two pathway enrichment analysis methods were conducted to explore the biological functions and molecular mechanisms of ZC3H15 in pan-cancer. Results: The results indicated that ZC3H15 was overexpressed in a wide range of tumors. In certain cancers, particularly LIHC, LUAD, BRCA, LUSC, and HNSC, its expression was significantly correlated with poor patient prognosis. Mutations and amplifications were the most common gene alterations in ZC3H15. The GSCA database showed that methylation levels were reduced in most tumor types. Abnormal expression of ZC3H15 was related to immune cell infiltration. Gene enrichment analysis indicated that ZC3H15-related genes involved in tumor progression were significantly enriched in multiple cell cycle processes. We demonstrated that knockdown of ZC3H15 suppressed cell proliferation, migration, and invasion in two liver cancer cell lines, MHCC97H and Huh7, and two BRCA cell lines, MDA-MB-231 and Hs 578T. To further clarify the functional mechanism, subsequent immunofluorescence staining confirmed that ZC3H15 knockdown induced prometaphase arrest in MHCC97H and Huh7 liver cancer cells. Conclusions: Overall, this pan-cancer study demonstrates that ZC3H15 serves as a potential biomarker for cancer diagnosis, prognosis, and immune cell infiltration.
- Open Access
- 16 April 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (9) , 4461-4476
METTL3-IGF2BP3 as a glucose sensor in hyperglycemic microenvironment promotes tumorigenesis and glycolysis
Glycemic disorders, especially diabetes characterized by elevated blood glucose, significantly increase the risk of various cancers, including increasing the risk of hepatocellular carcinoma (HCC) by 239%. Diabetes mellitus has now been confirmed as an independent risk factor for the development of HCC, with T2DM increasing the risk by 4.59 times. However, little is known about mechanisms regulate glucose signal transduction in HCC. We investigated the relationship between high glucose levels and methylation-related gene expression in HCC. The effects of METTL3-IGF2BP3 on transcriptome profiles were used to identify downstream molecules. Proliferation, glucose uptake, lactate production, ATP levels, extracellular acidification rate, and oxygen consumption rate were examined in HCC cells. The mechanism by which METTL3-IGF2BP3 activates the PI3K-AKT pathway was explored. The results showed that m6A modification levels were significantly elevated in HCC cells under a hyperglycemic microenvironment, primarily due to transcriptional activation of c-MYC-initiated METTL3. Additionally, glucose could directly bind to IGF2BP3 and promote its function in recognizing m6A sites. SLC39A10 as a downstream molecule of METTL3-IGF2BP3, promoting the uptake of Zn2+ in HCC. METTL3, IGF2BP3, or SLC39A10 silencing inhibited proliferation, colony formation, glycolysis in HCC cells. Mechanistically, silencing METTL3-IGF2BP3 significantly reduced the methylation level and function of SLC39A10, decreased intracellular Zn²⁺ levels, inhibited ADAM17 activity, and thus attenuated EGFR phosphorylation-induced PI3K-AKT pathway activation. Concurrently, alterations in intracellular Zn²⁺ levels are associated with altered immune cell infiltration in the HCC tumor microenvironment. In conclusion, the METTL3-IGF2BP3 axis promotes HCC tumorigenesis by enhancing glycolytic reprogramming and remodeling the immunosuppressive tumor microenvironment.
- 16 April 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (9) , 4461-4476
Open AccessMETTL3-IGF2BP3 as a glucose sensor in hyperglycemic microenvironment promotes tumorigenesis and glycolysis
Glycemic disorders, especially diabetes characterized by elevated blood glucose, significantly increase the risk of various cancers, including increasing the risk of hepatocellular carcinoma (HCC) by 239%. Diabetes mellitus has now been confirmed as an independent risk factor for the development of HCC, with T2DM increasing the risk by 4.59 times. However, little is known about mechanisms regulate glucose signal transduction in HCC. We investigated the relationship between high glucose levels and methylation-related gene expression in HCC. The effects of METTL3-IGF2BP3 on transcriptome profiles were used to identify downstream molecules. Proliferation, glucose uptake, lactate production, ATP levels, extracellular acidification rate, and oxygen consumption rate were examined in HCC cells. The mechanism by which METTL3-IGF2BP3 activates the PI3K-AKT pathway was explored. The results showed that m6A modification levels were significantly elevated in HCC cells under a hyperglycemic microenvironment, primarily due to transcriptional activation of c-MYC-initiated METTL3. Additionally, glucose could directly bind to IGF2BP3 and promote its function in recognizing m6A sites. SLC39A10 as a downstream molecule of METTL3-IGF2BP3, promoting the uptake of Zn2+ in HCC. METTL3, IGF2BP3, or SLC39A10 silencing inhibited proliferation, colony formation, glycolysis in HCC cells. Mechanistically, silencing METTL3-IGF2BP3 significantly reduced the methylation level and function of SLC39A10, decreased intracellular Zn²⁺ levels, inhibited ADAM17 activity, and thus attenuated EGFR phosphorylation-induced PI3K-AKT pathway activation. Concurrently, alterations in intracellular Zn²⁺ levels are associated with altered immune cell infiltration in the HCC tumor microenvironment. In conclusion, the METTL3-IGF2BP3 axis promotes HCC tumorigenesis by enhancing glycolytic reprogramming and remodeling the immunosuppressive tumor microenvironment.
- Open Access
- 29 September 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-11
A meta-analytic and systematic review to compare perioperative outcomes and prognosis between robotic and conventional (laparoscopic or open) liver resection in hepatocellular carcinoma cases
Hepatectomy can be performed via laparoscopic liver resection (LLR), open liver resection (OLR), and robotic liver resection (RLR). However, the advantages of RLR over LLR and OLR with respect to the prognosis and perioperative outcomes of individuals with hepatocellular carcinoma (HCC) remain unclear. This study was designed to compare the perioperative and prognostic outcomes of RLR with those of LLR and OLR in patients with HCC. A comprehensive literature search was conducted in Embase, the Cochrane Library, PubMed, and Web of Science using the following keywords: “liver resection,” “robotic,” and “hepatocellular carcinoma.” The primary endpoints were overall survival (OS) and recurrence-free survival (RFS), with outcomes expressed as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Secondary endpoints were perioperative outcomes, including resection margin status, intraoperative blood loss, transfusion requirement, operative time, conversion rate, postoperative complications, and length of hospital stay, reported as risk ratios (RRs) or mean differences (MDs) with 95% CIs. Eighteen studies involving 4,098 patients were included. Twelve studies reported the long-term prognosis of patients, with six comparing RLR with LLR, four comparing RLR with OLR, and two comparing RLR with LLR and OLR. Sixteen studies reported perioperative outcomes. The meta-analysis illustrated that RLR was associated with improved RFS (HR 0.78, 95% CI 0.64–0.94; p = 0.0092) and OS (HR 0.72, 95% CI 0.56–0.92; p = 0.0101) compared with LLR. No significant differences in OS and RFS were observed between RLR and OLR. Compared with LLR, RLR was associated with a lower conversion rate to laparotomy (RR 0.50, 95% CI 0.31–0.79; p = 0.0034) and a longer operative time (MD 30.69 min, 95% CI 9.56–51.82; p = 0.0044). RLR also resulted in significantly lower rates of overall complications (RR 0.60, 95% CI 0.37–0.98; p = 0.0402), severe complications (RR 0.41, 95% CI 0.24–0.70; p = 0.0011, respectively), and a shorter hospital stay (MD − 3.70 days, 95% CI − 4.80 to − 2.61; p < 0.0001). In patients with HCC, RLR is associated with superior prognosis and perioperative outcomes compared with LLR and RLR exhibits better perioperative outcomes than OLR.
- 29 September 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-11
Open AccessA meta-analytic and systematic review to compare perioperative outcomes and prognosis between robotic and conventional (laparoscopic or open) liver resection in hepatocellular carcinoma cases
Hepatectomy can be performed via laparoscopic liver resection (LLR), open liver resection (OLR), and robotic liver resection (RLR). However, the advantages of RLR over LLR and OLR with respect to the prognosis and perioperative outcomes of individuals with hepatocellular carcinoma (HCC) remain unclear. This study was designed to compare the perioperative and prognostic outcomes of RLR with those of LLR and OLR in patients with HCC. A comprehensive literature search was conducted in Embase, the Cochrane Library, PubMed, and Web of Science using the following keywords: “liver resection,” “robotic,” and “hepatocellular carcinoma.” The primary endpoints were overall survival (OS) and recurrence-free survival (RFS), with outcomes expressed as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Secondary endpoints were perioperative outcomes, including resection margin status, intraoperative blood loss, transfusion requirement, operative time, conversion rate, postoperative complications, and length of hospital stay, reported as risk ratios (RRs) or mean differences (MDs) with 95% CIs. Eighteen studies involving 4,098 patients were included. Twelve studies reported the long-term prognosis of patients, with six comparing RLR with LLR, four comparing RLR with OLR, and two comparing RLR with LLR and OLR. Sixteen studies reported perioperative outcomes. The meta-analysis illustrated that RLR was associated with improved RFS (HR 0.78, 95% CI 0.64–0.94; p = 0.0092) and OS (HR 0.72, 95% CI 0.56–0.92; p = 0.0101) compared with LLR. No significant differences in OS and RFS were observed between RLR and OLR. Compared with LLR, RLR was associated with a lower conversion rate to laparotomy (RR 0.50, 95% CI 0.31–0.79; p = 0.0034) and a longer operative time (MD 30.69 min, 95% CI 9.56–51.82; p = 0.0044). RLR also resulted in significantly lower rates of overall complications (RR 0.60, 95% CI 0.37–0.98; p = 0.0402), severe complications (RR 0.41, 95% CI 0.24–0.70; p = 0.0011, respectively), and a shorter hospital stay (MD − 3.70 days, 95% CI − 4.80 to − 2.61; p < 0.0001). In patients with HCC, RLR is associated with superior prognosis and perioperative outcomes compared with LLR and RLR exhibits better perioperative outcomes than OLR.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 539-552
Lasso-Based Nomogram for Predicting Early Recurrence Following Radical Resection in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is a common malignancy with a high recurrence rate following curative resection. This study aimed to identify factors contributing to early recurrence (within 2 years) and develop a Lasso-based nomogram for individualized risk assessment. Methods: We conducted a retrospective analysis of 206 hCC patients who underwent curative resection at Taizhou Hospital, Zhejiang Province, from January 2019 to August 2022. Patients were randomly divided into training (n=144) and validation (n=62) cohorts. Lasso regression was used to identify potential recurrence risk factors among 17 candidate predictors. A Cox proportional hazards model was constructed based on variables selected by Lasso. Model performance was assessed using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Five independent predictors of early HCC recurrence were identified: age, serum alanine aminotransferase (ALT) levels, cirrhosis, tumor diameter, and microvascular invasion (MVI). The nomogram demonstrated area under the curve (AUC) values for recurrence-free survival (RFS) of 0.828 (95% confidence interval [CI]: 0.753– 0.904) at 1 year, 0.799 (95% CI: 0.718– 0.880) at 2 years, and 0.742 (95% CI: 0.642– 0.842) at 5 years in the training cohort. The corresponding AUCs in the validation cohort were 0.823 (95% CI: 0.686– 0.960), 0.804 (95% CI: 0.686– 0.922), and 0.857 (95% CI: 0.722– 0.992) at 1, 2 and 5 years, respectively. Calibration curves and DCA confirmed the nomogram’s high accuracy and clinical utility. Conclusion: The Lasso-Cox regression nomogram effectively predicts HCC recurrence within two years post-hepatectomy, providing a valuable tool for personalized postoperative management to improve patient outcomes.
- 1 March 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 539-552
Open AccessLasso-Based Nomogram for Predicting Early Recurrence Following Radical Resection in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is a common malignancy with a high recurrence rate following curative resection. This study aimed to identify factors contributing to early recurrence (within 2 years) and develop a Lasso-based nomogram for individualized risk assessment. Methods: We conducted a retrospective analysis of 206 hCC patients who underwent curative resection at Taizhou Hospital, Zhejiang Province, from January 2019 to August 2022. Patients were randomly divided into training (n=144) and validation (n=62) cohorts. Lasso regression was used to identify potential recurrence risk factors among 17 candidate predictors. A Cox proportional hazards model was constructed based on variables selected by Lasso. Model performance was assessed using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Five independent predictors of early HCC recurrence were identified: age, serum alanine aminotransferase (ALT) levels, cirrhosis, tumor diameter, and microvascular invasion (MVI). The nomogram demonstrated area under the curve (AUC) values for recurrence-free survival (RFS) of 0.828 (95% confidence interval [CI]: 0.753– 0.904) at 1 year, 0.799 (95% CI: 0.718– 0.880) at 2 years, and 0.742 (95% CI: 0.642– 0.842) at 5 years in the training cohort. The corresponding AUCs in the validation cohort were 0.823 (95% CI: 0.686– 0.960), 0.804 (95% CI: 0.686– 0.922), and 0.857 (95% CI: 0.722– 0.992) at 1, 2 and 5 years, respectively. Calibration curves and DCA confirmed the nomogram’s high accuracy and clinical utility. Conclusion: The Lasso-Cox regression nomogram effectively predicts HCC recurrence within two years post-hepatectomy, providing a valuable tool for personalized postoperative management to improve patient outcomes.
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (10) , 5328-5338
Optimal preservation condition for the extraction of cell-free DNA from bile of patients with biliary tract cancer
Background: Patients with biliary tract cancer (BTC) often have dismal outcomes due to the poor performance of traditional methods for early diagnosis. Recently, bile cell-free DNA (cfDNA) has been reported as a potential liquid biopsy material for BTC diagnosis. However, bile is a complex alkaline aqueous medium, and the proper storage conditions for bile remain to be explored. The aim of this study is to explore the effects of storing bile under various conditions on the stability of bile cfDNA and to determine the optimal conditions, thereby establishing a foundation for the subsequent application of bile cfDNA in liquid biopsy for early diagnostic and prognosis monitoring of patients with malignant BTC. Methods: We evaluated the storage temperature and storage time for the preservation of bile samples. Bile samples were collected in cfDNA tubes with protectant covered inside or regular tubes without, and the stability of bile cfDNA was analyzed during 10 days at room temperature (RT) or after 2 months of storage at low temperatures. Results: Bile cfDNA remained stable for bile samples being collected with cfDNA tubes and stored for 10 days at RT, while degraded with time for the case with regular tubes. When bile samples were collected with cfDNA tubes and stored for 2 months at 4 ℃, bile cfDNA remained stable, however, if collected with regular tubes, bile cfDNA exhibited a slight loss of integrity. No significant difference was observed for 2 months storage at −20 or −80 ℃. Conclusions: Our findings suggested that for bile cfDNA research, bile samples should be collected with cfDNA tubes and it can be transported for short-term shipment at RT, and could be stored at 4 ℃ with cfDNA tubes, or frozen at −20 ℃ with regular tubes.
- 1 October 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (10) , 5328-5338
Open AccessOptimal preservation condition for the extraction of cell-free DNA from bile of patients with biliary tract cancer
Background: Patients with biliary tract cancer (BTC) often have dismal outcomes due to the poor performance of traditional methods for early diagnosis. Recently, bile cell-free DNA (cfDNA) has been reported as a potential liquid biopsy material for BTC diagnosis. However, bile is a complex alkaline aqueous medium, and the proper storage conditions for bile remain to be explored. The aim of this study is to explore the effects of storing bile under various conditions on the stability of bile cfDNA and to determine the optimal conditions, thereby establishing a foundation for the subsequent application of bile cfDNA in liquid biopsy for early diagnostic and prognosis monitoring of patients with malignant BTC. Methods: We evaluated the storage temperature and storage time for the preservation of bile samples. Bile samples were collected in cfDNA tubes with protectant covered inside or regular tubes without, and the stability of bile cfDNA was analyzed during 10 days at room temperature (RT) or after 2 months of storage at low temperatures. Results: Bile cfDNA remained stable for bile samples being collected with cfDNA tubes and stored for 10 days at RT, while degraded with time for the case with regular tubes. When bile samples were collected with cfDNA tubes and stored for 2 months at 4 ℃, bile cfDNA remained stable, however, if collected with regular tubes, bile cfDNA exhibited a slight loss of integrity. No significant difference was observed for 2 months storage at −20 or −80 ℃. Conclusions: Our findings suggested that for bile cfDNA research, bile samples should be collected with cfDNA tubes and it can be transported for short-term shipment at RT, and could be stored at 4 ℃ with cfDNA tubes, or frozen at −20 ℃ with regular tubes.
- Open Access
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1374245
A nomogram model for early recurrence of HBV-related hepatocellular carcinomas after radical hepatectomy
Background: To identify the risk factors and construct a predictive model for early recurrence of hepatitis B virus(HBV-)- related hepatocellular carcinomas(HCCs) after radical resection.Data and methods: A total of 465 HBV-related HCC patients underwent radical resections between January 1, 2012 and August 31, 2018.Their data were collected through the inpatient information management system of the First Affiliated Hospital of University of Science and Technology of China. Survival and subgroup analyses of early recurrence among male and female patients were performed using Kaplan-Meier curves. The independent risk factors associated with early postoperative tumor recurrence were analyzed using multivariate Cox proportional hazards regression model. Based on these independent risk factors, a risk function model for early recurrence was fitted, and a column chart for the prediction model was drawn for internal and external validation.Results: A total of 181 patients developed early recurrences, including 156 males and 25 females. There was no difference in the early recurrence rates between males and females. Tumor diameters>5cm, microvascular invasion and albumin level5 cm, microvascular invasion, and albumin level<35 g/L were independent risk factors for early recurrence. The prediction model based on three clinical indicators could predict early recurrence, with good discrimination, calibration, and extrapolation.
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1374245
Open AccessA nomogram model for early recurrence of HBV-related hepatocellular carcinomas after radical hepatectomy
Background: To identify the risk factors and construct a predictive model for early recurrence of hepatitis B virus(HBV-)- related hepatocellular carcinomas(HCCs) after radical resection.Data and methods: A total of 465 HBV-related HCC patients underwent radical resections between January 1, 2012 and August 31, 2018.Their data were collected through the inpatient information management system of the First Affiliated Hospital of University of Science and Technology of China. Survival and subgroup analyses of early recurrence among male and female patients were performed using Kaplan-Meier curves. The independent risk factors associated with early postoperative tumor recurrence were analyzed using multivariate Cox proportional hazards regression model. Based on these independent risk factors, a risk function model for early recurrence was fitted, and a column chart for the prediction model was drawn for internal and external validation.Results: A total of 181 patients developed early recurrences, including 156 males and 25 females. There was no difference in the early recurrence rates between males and females. Tumor diameters>5cm, microvascular invasion and albumin level5 cm, microvascular invasion, and albumin level<35 g/L were independent risk factors for early recurrence. The prediction model based on three clinical indicators could predict early recurrence, with good discrimination, calibration, and extrapolation.
- Open Access
- 12 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (7) , e7165
The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, it has a poor prognosis due to its highly invasive and metastatic nature. Consequently, identifying effective prognostic markers and potential therapeutic targets has been extensively investigated. METTL5, an 18S rRNA methyltransferase, is abnormally high in HCC. But its biological function and prognostic significance in HCC remain largely unelucidated. This study aimed to investigate the role of METTL5 in HCC progression, and elucidate its possible molecular mechanisms in HCC via transcriptome sequencing, providing new insights for identifying new HCC prognostic markers and therapeutic targets.Methods: The METTL5 expression in HCC and paracancerous tissues was analyzed using HCC immunohistochemical microarrays and bioinformatic retrieval methods to correlate METTL5 with clinicopathological features and survival prognosis. We constructed a METTL5 knockdown hepatocellular carcinoma cell line model and an animal model to determine the effect of METTL5 on hepatocellular carcinoma progression. Subsequently, RNA sequencing was performed to analyze the molecular mechanism of METTL5 in HCC based on the sequencing results, and relevant experiments were performed to verify it.Results: We found that METTL5 expression was elevated in hepatocellular carcinoma tissues and correlated with poor patient prognosis, and in the analysis of clinicopathological features showed a correlation with TNM staging. In hepatocellular carcinoma cell lines with knockdown of METTL5, the malignant biological behavior was significantly reduced both in vitro and in vivo. Based on the sequencing results as well as the results of GO functional enrichment analysis and KEGG pathway enrichment analysis, we found that METTL5 could promote the generation and release of neutrophil extracellular capture network (NETs) and might further accelerate the progression of HCC.Conclusion: The m6A methyltransferase METTL5 is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis. METTL5 accelerates malignant progression of HCC by promoting generation and release of the neutrophil extracellular traps (NETs) network, providing new insights for clinical biomarkers and immunotherapeutic targets in HCC prognosis.
- 12 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (7) , e7165
Open AccessThe m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, it has a poor prognosis due to its highly invasive and metastatic nature. Consequently, identifying effective prognostic markers and potential therapeutic targets has been extensively investigated. METTL5, an 18S rRNA methyltransferase, is abnormally high in HCC. But its biological function and prognostic significance in HCC remain largely unelucidated. This study aimed to investigate the role of METTL5 in HCC progression, and elucidate its possible molecular mechanisms in HCC via transcriptome sequencing, providing new insights for identifying new HCC prognostic markers and therapeutic targets.Methods: The METTL5 expression in HCC and paracancerous tissues was analyzed using HCC immunohistochemical microarrays and bioinformatic retrieval methods to correlate METTL5 with clinicopathological features and survival prognosis. We constructed a METTL5 knockdown hepatocellular carcinoma cell line model and an animal model to determine the effect of METTL5 on hepatocellular carcinoma progression. Subsequently, RNA sequencing was performed to analyze the molecular mechanism of METTL5 in HCC based on the sequencing results, and relevant experiments were performed to verify it.Results: We found that METTL5 expression was elevated in hepatocellular carcinoma tissues and correlated with poor patient prognosis, and in the analysis of clinicopathological features showed a correlation with TNM staging. In hepatocellular carcinoma cell lines with knockdown of METTL5, the malignant biological behavior was significantly reduced both in vitro and in vivo. Based on the sequencing results as well as the results of GO functional enrichment analysis and KEGG pathway enrichment analysis, we found that METTL5 could promote the generation and release of neutrophil extracellular capture network (NETs) and might further accelerate the progression of HCC.Conclusion: The m6A methyltransferase METTL5 is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis. METTL5 accelerates malignant progression of HCC by promoting generation and release of the neutrophil extracellular traps (NETs) network, providing new insights for clinical biomarkers and immunotherapeutic targets in HCC prognosis.
- Open Access
- 2 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 116, 109737
Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer
- 2 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 116, 109737
Open AccessMolecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer
- Open Access
- 23 August 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-9
Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study
A retrospective cohort study was conducted to collect 465 patients with hepatitis B-related hepatocellular carcinoma who had undergone radical hepatectomy from January 1, 2012, to August 31, 2018, at the First Affiliated Hospital of the University of Science and Technology of China. The clinical, pathological, and follow-up information was collected to compare the basic characteristics of death and nondeath after radical resection. KaplanMeier curves were used for survival analysis and male and female subgroup analysis. The multivariate Cox proportional-hazards regression model was used to analyze independent risk factors related to postoperative death. Of the 465 patients with radical resection of hepatitis B-related hepatocellular carcinoma, 132 died, and 1-, 3-, and 5-year cumulative survival rates after operation were 92.1, 78, and 64, respectively. In the male and female subgroup, 115 and 17 patients died, respectively. The 1-, 3-, and 5-year cumulative survival rates were 92.6, 77.0, and 62.6, respectively, in men, and 89.6, 78.8, and 70.2, respectively, in women. Multivariate Cox proportional-hazards regression analysis showed that microvascular invasion (MVI), Edmondson III/IV, BCLC stage B, and total bilirubin (TB)>20.5μmol/L were independent risk factors in patients with hepatitis B-related hepatocellular carcinoma after radical hepatectomy.
- 23 August 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-9
Open AccessLong-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study
A retrospective cohort study was conducted to collect 465 patients with hepatitis B-related hepatocellular carcinoma who had undergone radical hepatectomy from January 1, 2012, to August 31, 2018, at the First Affiliated Hospital of the University of Science and Technology of China. The clinical, pathological, and follow-up information was collected to compare the basic characteristics of death and nondeath after radical resection. KaplanMeier curves were used for survival analysis and male and female subgroup analysis. The multivariate Cox proportional-hazards regression model was used to analyze independent risk factors related to postoperative death. Of the 465 patients with radical resection of hepatitis B-related hepatocellular carcinoma, 132 died, and 1-, 3-, and 5-year cumulative survival rates after operation were 92.1, 78, and 64, respectively. In the male and female subgroup, 115 and 17 patients died, respectively. The 1-, 3-, and 5-year cumulative survival rates were 92.6, 77.0, and 62.6, respectively, in men, and 89.6, 78.8, and 70.2, respectively, in women. Multivariate Cox proportional-hazards regression analysis showed that microvascular invasion (MVI), Edmondson III/IV, BCLC stage B, and total bilirubin (TB)>20.5μmol/L were independent risk factors in patients with hepatitis B-related hepatocellular carcinoma after radical hepatectomy.
- 1 August 2021
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 20 (4) , 383-386
Low-pressure pulse flushing choledochoscopy combined with neodymium laser lithotripsy for the treatment of intrahepatic bile duct stones
- 1 August 2021
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 20 (4) , 383-386
Low-pressure pulse flushing choledochoscopy combined with neodymium laser lithotripsy for the treatment of intrahepatic bile duct stones